MCA38 Mouse Colon Carcinoma Tumor Growth Study
Objective: Test whether fractionated radiotherapy regimens synergize with anti-CTLA-4 antibody to induce tumor growth inhibition and abscopal effects in the MCA38 mouse colon carcinoma model
Gather these items before starting the experiment. Check off items as you prepare.
Equipment1
Not specified • Not specified • Not specified • Not specified
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Tumor cell injection
MCA38 mouse colon carcinoma cells were injected subcutaneously into syngeneic mice at two separate sites
Note: One site designated as primary (to be irradiated) and one as secondary (outside radiation field)
View evidence from paper
“MCA38 mouse colon carcinoma cells were injected s.c. into syngeneic mice at two separate sites, defined as a primary site that was irradiated, and a secondary site outside the radiotherapy field”
Tumor palpation and randomization
When both tumors became palpable, mice were randomly assigned to 8 treatment groups
Note: Randomization occurred after both tumors were palpable
View evidence from paper
“When both tumors were palpable mice were randomly assigned to 8 groups receiving no radiotherapy or 3 distinct regimens of radiotherapy”
Treatment group assignment
Mice were assigned to 8 groups: control (no treatment), radiotherapy alone (3 regimens), anti-CTLA-4 alone, or combination treatments
Note: Three radiotherapy regimens tested: 20 Gy single dose, 8 Gy × 3 fractions, or 6 Gy × 5 fractions
View evidence from paper
“8 groups receiving no radiotherapy or 3 distinct regimens of radiotherapy (20 Gy × 1, 8 Gy × 3 or 6 Gy × 5 fractions in consecutive days) in combination or not with 9H10 mAb against CTLA-4”
Radiotherapy administration
Primary tumors received radiotherapy according to assigned regimen while secondary tumors remained outside the radiation field
Note: Single dose: 20 Gy × 1; Fractionated: 8 Gy × 3 or 6 Gy × 5 fractions on consecutive days
View evidence from paper
“3 distinct regimens of radiotherapy (20 Gy × 1, 8 Gy × 3 or 6 Gy × 5 fractions in consecutive days)”
Anti-CTLA-4 antibody administration
9H10 monoclonal antibody against CTLA-4 administered to assigned groups in combination with radiotherapy or alone
Note: Timing and dosage of antibody administration not specified
View evidence from paper
“in combination or not with 9H10 mAb against CTLA-4”
Tumor monitoring
Mice were followed for tumor growth and regression at both primary and secondary sites
Note: Both primary (irradiated) and secondary (non-irradiated) tumors were monitored
View evidence from paper
“Mice were followed for tumors growth/regression”